Did Acadia Pharmaceuticals beat or miss consensus estimates last quarter?

What were the key takeaways from Acadia Pharmaceuticals’s earnings call?

What factors drove the changes in Acadia Pharmaceuticals's revenue and profit?

What is Acadia Pharmaceuticals's gross profit margin?

What is Acadia Pharmaceuticals's latest dividend and current dividend yield?

What were the key takeaways from Acadia Pharmaceuticals's earnings call?

What is the revenue and EPS growth rate for Acadia Pharmaceuticals year over year?

What does Acadia Pharmaceuticals do and what are its main business segments?

- **Revenue Milestone**: FY25 adjusted revenue surpasses $1 billion for first time at $1.08 billion (14% YoY growth).
- **NUPLAZID Growth**: Q4 net sales $189 million (17% YoY); 2026 guidance $760-790 million (10-14% growth).
- **DAYBUE Expansion**: Q4 sales $110 million (13% YoY); 2026 STIX-driven growth to $460-490 million.
- **Pipeline Momentum**: Remlifanserin Phase II ADP readout expected Q3 2026; ACP-271 first-in-human study begins Q1 2026.
- **Financial Strength**: FY26 total revenue guidance $1.22-1.28 billion; $250 million one-time tax benefit.

**【CEO Summary Section】**
- ACADIA achieved record Q4 2025 revenues of $298 million (16% YoY), with full-year adjusted revenue surpassing $1 billion for the first time at $1.08 billion (14% YoY growth).
- NUPLAZID net sales: $189 million (Q4) / $692 million (FY25), up 17% and 15% YoY, with 2026 guidance of $760-790 million (10-14% growth).
- DAYBUE net sales: $110 million (Q4) / $391 million (FY25), up 13% and 12% YoY, with 2026 guidance of $460-490 million (18-25% growth) driven by STIX launch.
- Long-term goal: NUPLAZID to reach $1 billion in 2028; DAYBUE to $700 million in 2028 (15% from EU).

**【CFO Financial Commentary】**
- Q4 2025 GAAP total revenue: $284 million; FY25 GAAP total revenue: $1.07 billion.
- NUPLAZID gross-to-net: 29.4% (Q4) / 25.9% (FY25); DAYBUE gross-to-net: 19.5% (Q4) / 22.3% (FY25).
- FY26 financial guidance: Total revenue $1.22-1.28 billion; R&D expenses $385-410 million; SG&A expenses $660-700 million.
- One-time tax benefit of $250 million from valuation allowance release.

**【Commercial Update (Tom Garner)】**
- NUPLAZID: Q4 volume growth 13%, new prescriptions up 18% YoY; 2026 guidance reflects 12% CAGR to $775 million midpoint.
- DAYBUE: Q4 sales $110 million (13% YoY); STIX launch in Q2 2026 targeting 400+ additional patients.
- Global named patient programs driving 76% of new prescriptions from community physicians.

**【Pipeline Update (Liz Thompson)】**
- Remlifanserin: Phase II ADP readout expected Aug-Oct 2026; Phase II LBDP study initiated.
- Trofinetide: Japan Phase III study initiated; EU CHMP negative trend vote (reexamination requested).
- ACP-271: First-in-human study to begin Q1 2026; targeting Huntington's disease and TD.
- FY26 pipeline catalysts: 5 Phase II/III studies initiated; 4 readouts by end-2027.

**【Q&A Highlights】**
- Remlifanserin differentiation: Once-daily dosing, no DDIs, safety profile similar to NUPLAZID.
- DAYBUE STIX: Early interest from 400+ patients; 2026 sales growth driven by U.S. launch and named patient programs.
- Regulatory risks: EU trofinetide approval delay; potential Cobenfy competition in ADP.
- Financial flexibility: $820 million cash balance; no near-term M&A plans.

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 2025 total revenue $278.6M (+11% YoY), driven by DAYBUE (+11%) and NUPLAZID (+12%).
- **Strategic Investments**: 30% NUPLAZID field force expansion (50 reps) for Q1 2026; DAYBUE Europe launch planned Q1 2026.
- **Pipeline Momentum**: ACP-204 Phase II initiated; ACP-211 Phase II to start Q4 2025; trofinetide Phase III in Japan.
- **Financial Strength**: $847M cash; updated 2025 guidance: NUPLAZID $685-695M, DAYBUE $385-400M.

**【CEO Opening Remarks】**
- Total Q3 2025 revenue: $278.6M (+11% YoY), driven by DAYBUE ($101.1M, +11%) and NUPLAZID ($177.5M, +12%).
- DAYBUE achieved 1,006 unique global patients, highest quarterly volume. NUPLAZID saw record sales and 21% YoY referral growth.
- Pipeline momentum: Phase II (ACP-204) and Phase III (trofinetide) trials initiated; ACP-211 Phase II to start Q4 2025.

**【Tom Garner - Commercial Update】**
- DAYBUE: 74% of Q3 scripts from community physicians, 40% U.S. market penetration. 1,006 global patients, 50%+ 12-month persistency.
- NUPLAZID: 9% volume growth, 26% new prescribers. 30% field force expansion planned for Q1 2026.
- International DAYBUE named patient programs active in EU, Israel, Latin America.

**【Elizabeth Thompson - Pipeline Update】**
- ACP-204 (Lewy body psychosis): Phase II initiated; targeting 0.4 effect size on SAPS-H+D scale.
- Trofinetide: Phase III in Japan; EU CHMP opinion expected Q1 2026.
- ACP-211 (MDD): Phase II to start Q4 2025; designed to avoid ketamine-like side effects.
- 4 major readouts expected 2026-2027: ACP-204, ACP-101, trofinetide, ACP-271.

**【Mark Schneyer - Financial Review】**
- Q3 2025: GAAP revenue $278.6M, R&D $87.8M, SG&A $133.4M.
- Updated 2025 guidance: NUPLAZID $685-695M, DAYBUE $385-400M (including named patient sales).
- Cash balance: $847M, supporting 2026 growth investments.

**【Q&A Highlights】**
- NUPLAZID field force expansion: 50 new reps targeting primary care, NPs, PAs. 26% new prescribers in Q3.
- DAYBUE Europe: Germany launch planned post-CHMP opinion (Q1 2026), with Italy/France named patient programs.
- ACP-204: Phase II powered for 0.4 effect size; QTc safety profile differentiated from pimavanserin.
- ACP-211: Phase II to test efficacy vs. SPRAVATO with reduced dissociation/sedation risk.

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 total revenue $264.6M (+9% YoY), DAYBUE $96.1M (+14%), NUPLAZID $168.5M (+7%).
- **DAYBUE Momentum**: 987 unique patients, 12-month persistency >50%, 70% on therapy >12 months.
- **NUPLAZID Expansion**: Referrals +17% YoY, DTC campaign drives 17x YoY website traffic.
- **Pipeline Progress**: 9 programs in development, ACP-101 readout Q4, ACP-204 ADP study starting Q3.
- **Guidance Update**: NUPLAZID raised to $665-690M, cash balance $762M, tax rate mid-teens short-term.

**【CEO Opening Remarks】**
- Total Q2 revenue of $264.6 million, up 9% YoY, driven by 14% growth in DAYBUE and 7% in NUPLAZID.
- DAYBUE sales reached $96.1 million, with 987 unique patients, reflecting 12-month persistency >50% and expansion into community settings.
- NUPLAZID revenue of $168.5 million, up 7% YoY, supported by 17% YoY increase in referrals and DTC campaign success.
- Raised NUPLAZID guidance to $665-690 million (from $650-690 million) and extended the More to Parkinson's campaign with Ryan Reynolds.

**【Commercial Update】**
- DAYBUE: 900+ new HCP writers in community settings, 70% of patients on therapy >12 months, and 18-month persistency rate >45%.
- NUPLAZID: 5% volume growth, highest bottles shipped since launch, and 17x YoY increase in consumer website traffic.
- Global expansion for DAYBUE with named patient supply in EU, Israel, and ROW.

**【Pipeline Update】**
- 9 programs in development, including ACP-211 (deuterated norketamine) and ACP-271 (GPR88 agonist).
- Upcoming milestones: Phase III trofinetide in Japan (Q3), ACP-101 PWS readout (Q4), and ACP-204 ADP readout (Q4).
- R&D Day highlighted DAYBUE's long-term impact and pipeline breadth, with 5 Phase II/III readouts expected by 2027.

**【Financials】**
- GAAP net loss of $109.3 million, driven by $78 million R&D and $133.5 million SG&A expenses.
- Cash balance of $762 million, up from $681.6 million Q1.
- Tax rate guidance: mid-teens short-term, mid-20s long-term, with potential IRA impact from 2029.

**【Q&A Highlights】**
- DAYBUE: 75% of new patients from community settings, 900+ new HCP writers, and 12-month persistency >50%.
- NUPLAZID: 17% YoY referral growth, DTC campaign extension, and 2026 growth driven by field force expansion.
- Pipeline: ACP-101 Phase III readout in Q4, ACP-204 ADP study starting Q3, and ACP-271 first-in-human trial in Q4.
- Financial: No inventory issues, tax rate considerations, and IRA eligibility for NUPLAZID in 2029.

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 total revenue up 19% YoY ($244.3M), driven by DAYBUE (+11%) and NUPLAZID (+23%).
- **DAYBUE Momentum**: 954 unique patients (all-time high), 65% on therapy >12 months, and 35% sequential drop in discontinuations.
- **ACP-101 Acceleration**: Phase 3 results expected Q4 2025, targeting hyperphagia in Prader-Willi syndrome.
- **Global Expansion**: Managed access programs in Europe and named patient access agreements in 10+ countries.
- **Financial Strength**: $681.6M cash balance, with R&D spend updated to $330-350M for 2025.

**【CEO Opening Remarks】**
- ACADIA achieved a strong start in Q1 2025 with total revenue of $244.3 million, up 19% YoY, driven by DAYBUE and NUPLAZID performance.
- DAYBUE sales reached $84.6 million (+11% YoY), with 954 unique patients (all-time high), reflecting reduced discontinuations and improved persistency.
- NUPLAZID revenue was $159.7 million (+23% YoY), supported by volume growth and consumer engagement campaigns.
- R&D pipeline updates include accelerated timelines for ACP-101 (Phase 3 in Prader-Willi syndrome) and ACP-204 (Alzheimer's disease psychosis and Lewy Body Dementia).

**【COO Commercial Update】**
- DAYBUE: Sequential patient growth (+35% reduction in discontinuations), expanded field force, and 65% of active patients on therapy >12 months.
- NUPLAZID: Q1 2025 best quarterly performance since 2020, with 6% volume growth and 30% increase in disease awareness engagement.
- Global expansion: Managed access programs in Europe (Germany, France) and distribution agreements for named patient access in Latin America, Middle East, and Asia Pacific.

**【CFO Financial Highlights】**
- Q1 2025 GAAP net income: $244.3 million revenue, with DAYBUE gross net adjustment of 24.9% and NUPLAZID at 24.1%.
- R&D expenses: $78.3 million (+28% YoY) due to clinical trial acceleration; updated 2025 guidance: $330-350 million.
- Cash balance: $681.6 million, with positive cash flow from operations despite $98.8 million milestone payments to Neuren.
- Inventory stability: Sufficient NUPLAZID and DAYBUE supplies to meet demand through mid-2030s.

**【Q&A Key Takeaways】**
- **ACP-101 (Carbetocin):** Top-line data expected Q4 2025; statistically significant hyperphagia reduction key for FDA filing.
- **Europe Pricing:** Confident in strong pricing reflecting DAYBUE's value; monitoring Most Favored Nation (MFN) developments post-approval.
- **Patient Retention:** DAYBUE persistency >50% at 12 months, with no correlation between age/weight and discontinuation rates.
- **Supply Chain:** Tariff risks mitigated by U.S. inventory; no immediate supply chain disruptions anticipated.
- **BD Strategy:** Actively pursuing rare disease assets with high medical need, focusing on commercializable pipeline additions.

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

- **Commercial Growth**: 2024 U.S. revenue up 32% to $957.8M. DAYBUE (+97%) and NUPLAZID (+11%) drive >$1B 2025 target.
- **Pipeline Expansion**: 4 late-stage programs (ACP-101, ACP-204, ACP-711, trofinetide) with EU approvals and Phase III reads in 2025-2026.
- **Strategic Moves**: $146.5M priority review voucher sale strengthens balance sheet to $756M.
- **Operational Momentum**: 62% of DAYBUE patients stable >12 months, NUPLAZID market share up to 25%.
- **Global Ambition**: First ex-U.S. revenue in 2025, EU trofinetide approval Q1 2026.

**【CEO Summary Section】**
- Catherine Owen Adams highlighted 2024 achievements: DAYBUE and NUPLAZID revenue growth, pipeline expansion (ACP-204 for Lewy Body Dementia Psychosis, ACP-711 for essential tremor), and strategic moves like the $146.5M priority review voucher sale.
- 2025 targets include >$1B U.S. commercial revenue, EU trofinetide approval (Q1 2026), and R&D Day on June 25.

**【Commercial Performance】**
- **DAYBUE**: Q4 sales $96.7M (11% YoY), full year $348.4M (97% YoY growth). 62% of patients on therapy >12 months, 90% of Q4 volume from stable patients. 2025 U.S. net sales guidance $380M-$405M, with ex-U.S. managed access revenue.
- **NUPLAZID**: Q4 sales $162.9M (13% YoY), full year $609.4M (11% YoY). 25% market share in atypical antipsychotics for Parkinson's hallucinations. 2025 net sales guidance $650M-$690M.

**【Pipeline Updates】**
- **Trofinetide**: EU MAA submitted, Japan Phase III planned Q3 2024. Managed access programs in select ex-U.S. markets.
- **ACP-101 (Prader-Willi)**: Phase III COMPASS-PWS expected fully enrolled Q4 2024, top-line data H1 2026.
- **ACP-204**: Phase II in Alzheimer's psychosis (enrollment Q1 2025), Phase II in Lewy Body Dementia Psychosis (Q3 2024 start).
- **ACP-711 (essential tremor)**: Phase II planned 2026, targeting GABA alpha 3 receptor.

**【Financial Highlights】**
- 2024 total revenue $957.8M (32% YoY growth). DAYBUE gross to net 18.8%, NUPLAZID 26.1%.
- 2025 guidance: $1.03B-$1.095B revenue. R&D expenses $310M-$330M, SG&A $535M-$565M. Cash balance $756M (up from $439M YoY).

**【Q&A Highlights】**
- **DAYBUE**: Q1 2025 sales decline expected due to Q4 pull-forward ($3.5M), Medicare Part D redesign. Long-term gross to net ~20-25%. 70% of Rett patients未尝试DAYBUE.
- **NUPLAZID**: DTC campaign boosted unbranded website traffic. 2025 gross to net reduction (300bps) due to Medicare Part D phase-in.
- **ACP-101**: Primary endpoint: hyperphagia reduction. Secondary endpoints: caregiver-reported behavior changes. Open-label extension shows patient persistence.
- **EU Strategy**: Trofinetide approval Q1 2026, managed access programs in 2025. Team building for commercial launch.


Actual												-0.57	-0.27	-0.54	-0.42	-0.42	-0.27	-0.09	-0.27	-0.7	-0.21	-0.17	-0.26	-0.27	0.01	-0.4	0.28	0.1	0.2	0.2	0.86	0.11	0.16	0.42	1.6
Forecast												-0.4783	-0.4392	-0.3835	-0.4736	-0.5299	-0.3045	-0.2595	-0.2376	-0.6179	-0.2478	-0.1942	-0.2471	-0.2145	-0.0978	-0.4477	0.2889	0.0488	0.1777	0.1381	0.2157	0.0867	0.1381	0.1729	0.137
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-19.17%	+38.52%	-40.81%	+11.32%	+20.74%	+11.33%	+65.32%	-13.64%	-13.29%	+15.25%	+12.46%	-5.22%	-25.87%	+110.22%	+10.65%	-3.08%	+104.92%	+12.55%	+44.82%	+298.70%	+26.87%	+15.86%	+142.91%	+1067.88%

Actual	--	--	--	--	--	--	--	--	--	--	--	90.07M	110.10M	120.58M	121.01M	106.55M	115.22M	131.61M	130.76M	115.47M	134.56M	130.71M	136.49M	118.46M	165.24M	211.70M	231.04M	205.83M	241.96M	250.40M	259.60M	244.32M	264.57M	278.63M	283.99M
Forecast	--	--	--	--	--	--	--	--	--	--	--	90.75M	103.41M	118.82M	122.76M	112.01M	124.90M	127.93M	135.39M	121.91M	130.41M	138.76M	134.23M	120.06M	166.18M	192.32M	223.79M	208.31M	235.95M	248.83M	255.61M	238.77M	262.02M	276.54M	292.79M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.75%	+6.47%	+1.48%	-1.43%	-4.87%	-7.75%	+2.88%	-3.42%	-5.29%	+3.19%	-5.80%	+1.68%	-1.33%	-0.57%	+10.08%	+3.24%	-1.19%	+2.55%	+0.63%	+1.56%	+2.32%	+0.97%	+0.76%	-3.00%

ACAD

ACAD fundamentals

ACAD Q4 2025 Earnings

Earnings Call

You can ask Aime

ACAD

ACAD fundamentals

ACAD Q4 2025 Earnings

Earnings Call

ACAD Earnings Call Summary for Q4/20254:30 PM on Feb 25, 2026

ACAD Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

ACAD Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

ACAD Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

ACAD Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime